Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.
about
INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologistEffects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studiesLEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.Higher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional studyExenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failureTwenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.The influence of body composition on the N-terminal pro-B-type natriuretic peptide level and its prognostic performance in patients with acute coronary syndrome: a cohort study.Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilizationLiraglutide: a review of its use in the management of obesity.GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis.Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.Natriuretic peptides in the control of lipid metabolism and insulin sensitivity.Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators.Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.
P2860
Q28083473-F9B6B44F-8B1C-4B26-943C-3EDE02513743Q30983590-E1F1B3FB-D3D9-4E85-8331-58B3501F5283Q31044140-6C211A39-C6FC-4EDA-9DA9-894D153803FDQ35080171-31CAF679-2705-4A18-92C9-6B35C4BEC056Q35082511-D0C6047E-7B16-4DE4-8C26-7B7ACBAAE334Q36023385-D78CCA0D-5EE1-4C22-B34E-6489B1EB34CBQ36428904-C61E2EEE-E3F0-4453-A19E-0BE14F6284FDQ36454284-CC5B9A67-C3D5-489A-B8C4-E4140B13CD70Q36757419-20C31F6B-E160-493D-B198-41AA121CF0D9Q36769441-BE3E9696-C49E-43E5-8E2F-2F685462F77DQ36902536-7EA125DD-01DA-4296-ACB7-51C24ED4F1A0Q38488650-A3B991D5-ECCB-42BC-98F4-3FCE094DA77CQ38709406-BA2BB080-EB68-4322-8787-A1EA62EADCE9Q39114140-98A2093D-4FF8-43EC-B412-8C80C6115782Q40988787-F9DEA6B2-B52F-4371-93A1-D0644C62B9CDQ41811427-7D4E375B-210D-453E-8A01-AB0452B7BFA9Q43019863-B188A476-683D-42F7-A7D7-6EB924A7E268Q48042778-07F354F4-E78A-4A02-8696-66210439A814Q50122007-C87B89D6-1376-44DF-A5E2-1DA784F2C022Q50214064-0F24BC92-2FED-4E1B-8F9B-6E7A16603860Q52338665-E65E9FB5-F7D5-4EBF-A766-8911716FD735
P2860
Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Changes in liraglutide-induced ...... bese type 2 diabetic patients.
@en
Changes in liraglutide-induced ...... bese type 2 diabetic patients.
@nl
type
label
Changes in liraglutide-induced ...... bese type 2 diabetic patients.
@en
Changes in liraglutide-induced ...... bese type 2 diabetic patients.
@nl
prefLabel
Changes in liraglutide-induced ...... bese type 2 diabetic patients.
@en
Changes in liraglutide-induced ...... bese type 2 diabetic patients.
@nl
P2093
P2860
P356
P1476
Changes in liraglutide-induced ...... bese type 2 diabetic patients.
@en
P2093
Chun-Jun Li
Qiu-Mei Zhang
Tie-Lian Yu
P2860
P2888
P356
10.1186/1475-2840-13-36
P407
P577
2014-02-05T00:00:00Z
P5875
P6179
1046661237